Ryohei Kozaki

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Acute Lymphoblastic Leukemia

Tyrosine Kinase

Diffuse Large B Cell Lymphoma

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Ryohei Kozaki, Tomoko Yasuhiro, Hikaru Kato, Jun Murai, Shingo Hotta, Yuko Ariza, Shunsuke Sakai, Ryu Fujikawa, Takao Yoshida
Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. PloS one 18 (3) (2023)
Ryohei Kozaki, Tomoko Yasuhiro, Hikaru Kato, Jun Murai, Shingo Hotta, Yuko Ariza, Shunsuke Sakai, Ryu Fujikawa, Takao Yoshida
Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. PloS one 18 (3) (2023)
Ryohei Kozaki, Tomoko Yasuhiro, Hikaru Kato, Jun Murai, Shingo Hotta, Yuko Ariza, Shunsuke Sakai, Ryu Fujikawa, Takao Yoshida
Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. PloS one 18 (3) (2023)
Ryohei Kozaki, Tomoko Yasuhiro, Hikaru Kato, Jun Murai, Shingo Hotta, Yuko Ariza, Shunsuke Sakai, Ryu Fujikawa, Takao Yoshida
Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. PloS one 18 (3) (2023)
Ryohei Kozaki, Meike Vogler, Harriet Sarah Walter, Sandrine Jayne, David Dinsdale, Reiner Siebert, Martin J S Dyer, Toshio Yoshizawa
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. Cancers 10 (4) (2018)